Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Avian IgY antibodies and their recombinant equivalents in research, diagnostics and therapy

Edzard Spillner a,*, Inge Braren b, Kerstin Greunke a, Henning Seismann a, Simon Blank a, Dion du Plessis c

a Institute of Biochemistry and Molecular Biology, Department of Chemistry, University of Hamburg, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany
b Hamburg Center for Experimental Therapy Research (HEXT), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
c Immunology Section, Onderstepoort Veterinary Institute, Onderstepoort, Pretoria 0110, South Africa

1. Introduction

Antibodies are likely to remain the affinity molecules of choice in a wide variety of analytical, biochemical, and medical approaches. This is primarily because they have familiar properties and their use is well-established in many applications. Moreover, their specificities and biological effects can now be readily manipulated using standard molecular biological techniques. In most cases mammalian antibodies are perfectly adequate. Unfortunately, their involvement in the immune response and immune-mediated pathologies along with a high degree of conservation among mammals can, however, make them susceptible to unwanted interactions with conserved proteins, which can in turn hamper their use in certain approaches.

The immunization of chickens provides an attractive alternative to using mammals as hosts for antibody production. IgY is the major low molecular weight immunoglobulin in oviparous animals.

This type of antibody has distinctive properties which can be exploited in various ways in research, diagnostics and therapy. One important advantage arises from the phylogenetic distance and genetic background that distinguishes birds from mammals. This improves the likelihood that an immune response will be elicited against antigens or epitopes that may be non-immunogenic in mammals. The deposition of IgY into the egg yolks of the immunized bird then provides an elegant source of polyclonal immunoglobulins. Since polyclonal IgY can be recovered from the eggs of laying hens for prolonged periods, this approach provides a long-term supply of substantial amounts of antibodies. In addition, such antibodies exhibit biochemical and structural features, which can render them superior in virtually all types of immunoassays, especially those designed to detect molecules in specimens like mammalian blood or serum [4,5].

Due to the technical difficulties of avian hybridoma techniques, and the problem that existing immortalized B cell lines (such as the ALV-induced bursa-derived lymphoma line DT40) undergo Ig gene conversion during in vitro culture [6], the production of chicken antibodies languished somewhat until it became possible to generate monoclonal IgY through the in vitro selection from...
combinatorial antibody libraries by phage display [7]. In the chicken, only a single functional V and J segment is present in the light and heavy chain gene loci. As a result, diversification of the avian immune repertoire is introduced into the rearranged V(D)J segments by gene conversion using pseudo V genes as donors. As will be seen, this greatly simplifies the construction of combinatorial recombinant antibody libraries while the selective power of phage display provides a way of accessing unique binders.

This review focuses on the immunological background and novel approaches that have been made possible as a result of avian antibody technologies. It suggests that the chicken can be more widely used for generating both native, and recombinant IgY.

2. Immunological, structural and biochemical characteristics

IgY is the predominant low molecular weight serum immunoglobulin isotype in amphibians, reptiles, and birds. This designation derives from its occurrence in egg yolk, and, as demonstrated in 1893, it transfers immunity from the hen to the developing embryo [8].

Among the three avian isotypes (IgY, IgM and IgA), IgY is the most abundant in serum, with concentrations ranging from 5 to 15 mg/ml in laying hens [9,10] compared to the lower concentrations of IgM (0.001–0.01 mg/ml) and IgA (0.3–0.5 mg/ml). In anseriform birds like ducks there exists in addition to IgY, an alternatively spliced version of IgY, the IgY ∆Fc. This variant lacks the Fc region and therefore does not have the Fc-mediated secondary effector functions. It is also found in relatively substantial quantities (1–3 mg/ml) [11].

The organs in the chicken responsible for antibody production differ significantly from those in mammals. The central (primary) lymphoid organs are represented by the thymus and bursa of Fabricius (BF), while peripheral (secondary) lymphoid organs include the spleen, Harderian glands, bone marrow, conjunctival-associated lymphoid tissue (CALT), bursal-associated lymphoid tissue (BALT) and gut-associated lymphoid tissue (GALT). Chickens do not have lymph nodes as such, but instead have lymphoid nodules associated with the lymphatics [12].

The BF is located above the cloaca in the caudal body cavity and plays a cardinal role in avian B cell development and antibody diversification [13]. Following colonization by a small number of B cell precursors, cells expressing surface immunoglobulin undergo rapid proliferation such that at about two months of age there are approximately 10^4 follicles in the BF [14]. A few weeks after hatching, about 5% of the bursal cells migrate each day into the blood and then into the spleen, thymus, and caecal tonsils, where they subsequently produce immunoglobulins. The spleen is the largest secondary lymphoid organ and is important for antigen processing and in the production of antibodies after hatching [15].

Although IgY is essentially an immunoglobulin with characteristics and functions similar to IgG, it possesses a slightly different structure which provides its distinct properties and biochemical behaviour. IgY has a slightly higher molecular mass (approximately 167 kDa) than its mammalian counterpart [16] due to the presence of four constant- and one variable Ig heavy chain domains. The nucleotide sequence of the chicken upsilon (υ) heavy chain [17] reveals that as with the more ancient amphibian IgY [18,19], the avian molecule contains a domain (C2δ) which is conserved in mammalian IgE, but was condensed to form the flexible ‘hinge’ region in mammalian IgG [17]. An orthologous domain must therefore have existed in the IgY-like ancestor prior to duplication and subsequent divergence from the mammalian lineage.

In mammals, IgG forms immune complexes and facilitates opsonisation, activates the complement system and provides protection for the foetus upon transport across the placenta. IgE can sensitize effector cells and mediates anaphylactic reactions [20]. IgY appears to combine mammalian IgG- and IgE-like functions since it not only provides defence against infections [21], but may also mediate anaphylaxis [22]. In contrast to mammals, basophils are much more numerous in birds than mast cells [23] and antibody-dependent hypersensitivity and fatal systemic anaphylaxis [22,24,25] are mainly mediated by these cells [26]. This constitutes indirect evidence for the presence of IgY receptors on effector cells. IgY binds to monocytes with IgG-like kinetics [27], despite its putative IgE like structure as predicted from the chicken υ heavy chain primary sequence [17]. Recently, the chicken leucocyte receptor complex (LRC) was analysed and four major types of chicken Ig-like receptors (CHIR) were identified: CHIR-A, activating receptors displaying two extracellular C2-type Ig-domains, CHIR-B, inhibitory receptors also displaying two C2-like Ig-domains, and two types of CHIR-AB with one or two C2-like Ig-domains, which are reported to have bifunctional potential, since they display features of both inhibitory and activating receptors [28,29]. So far, CHIR-AB1 and its recently identified homologues are the only receptors in the LRC of known specificity [30]. It functions as a classical Fc receptor expressed on chicken B cells, macrophages, monocytes, and NK cells [31]. In contrast to IgG and IgE receptors, CHIR-AB1 binds in a similar way as FcγRI or FcγRII with a 2:1 stoichiometry. Its affinity is comparable with the values reported for IgA binding to its receptor [32]. In contrast to mammalian IgG or IgE the CHIR-AB1 binding site was mapped to the upsilon heavy chain domains 3 and 4 (C3/C4) interface, a finding that together with the phylogenetic relationship of the antibodies and their receptors indicates a substantial shift in the nature of Fc receptor binding during evolution [33,34]. A specific interaction between CHIR-AB1, which provides an inhibitory motif in its cytoplasmic tail and the Fc portion of IgY was shown to enhance calcium release in a chicken B cell line expressing CHIR-AB1 and the common activating γ-chain [31]. The activation required aggregation of IgY suggesting that immune complexes are required to trigger a response [31]. By comparing CHIR-AB1-like sequences in databases, 18 homologues of CHIR-AB1 have been identified and cloned. These comprised non-IgY-binding and IgY-binding isoforms displaying different affinities [30].

An additional FcR-related gene designated Gallus gallus FcR (ggFcR) was recently identified [35]. The receptor which selectively binds IgY consists of four extracellular C2-set Ig domains. Surprisingly, ggFcR is closely related to chicken LCR encoded genes, but is located on chromosome 20 distinct from the LCR and Fcγ recombination clusters. Recently a chicken yolk sac IgY receptor (FcRY) responsible for IgY transport from yolk to the embryonic circulation was characterized as a homologue of the mammalian phospholipase A2 receptor (PLA2R), a member of the mannose receptor family [36]. Deposition in the yolk however is mediated by another receptor not yet cloned [10] the specificity of which has been addressed by different approaches. One factor restricting the deposition of IgM and IgA in the yolk appears to be their polymeric nature [37]. The Fc region structure may also be important since anseriform species like ducks preferentially incorporate full-length IgY into the egg yolk over the truncated isoform IgY ∆Fc [38]. Site-specific mutagenesis experiments using mammalian IgG sequences and extrapolation of this information to the upsilon heavy chain suggested the C2/C3 interface, especially residues 362–365, and positions 550–553 within C4 as essential for the interaction with the receptor [39]. Besides its function and interaction with Fc receptors, IgY differs from IgG in a variety of aspects which are more directly attributable to the molecule itself. As mentioned earlier, the phylogenetic distance between the avian immune system and mammalian proteins most likely increases the immune response towards the respective antigens. This means that IgY can often be raised against epitopes on highly conserved proteins when...
other mammals fail to provide an immunological response [40,41]. The extent to which the overall antibody affinities of mammalian IgG and IgY relate to each other is still under investigation but monoclonal IgY antibody fragments generally exhibit reactivities at least comparable to those of IgG (unpublished observations).

Compared to mammalian IgG, IgY is lacking the flexible hinge region and, thus, thought to be a more rigid immunoglobulin. This hinge-less structure is also found in mammalian IgE. IgY therefore exhibits structural features of both mammalian IgE and IgG, a finding also supported by a structural analysis of the IgY Fc portion [42]. Potentially reduced molecular flexibility might be associated with decreased susceptibility to proteolytic degradation or fragmentation. Nevertheless, IgY can be fragmented by papain or trypsin [43]. IgY, like mammalian IgG, is reasonably stable and can be stored for several months under standard conditions [44]. A serious limitation of IgY for therapeutic applications, however, is its reduced stability at low pH [44,45]. In contrast to IgG the antigen binding activity of IgY decreases significantly under acidic conditions. As demonstrated by circular dichroism analyses, loss of activity of chicken IgY is accompanied by significant conformational changes, a fact attributed to fewer intramolecular disulphide linkages than, for example, rabbit IgG [46].

3. Generation of polyclonal and monoclonal IgY

Today, production of polyclonal IgY by immunization of chickens is offered on a routine basis by several commercial companies. In general, this approach is subject to the same constraints as the conventional immunization of mammals. Nevertheless, the advantages of chickens being a non-mammalian species [47] and the bloodless isolation of immunoglobulins have perhaps not yet been fully appreciated and exploited.

Egg yolk collected after immunization can provide concentrations of IgY in the range of 10 mg/ml as starting source for the recovery of the immunoglobulin. Relatively simple methods may be used to extract the antigen-specific immunoglobulin from egg yolk with several commercial kits being available. The decision to use a particular protocol is usually brought about by the intended downstream applications as well as the expertise and equipment available [48]. One of the most frequently used procedures involves protein precipitation with ammonium sulphate, dextran sulphate or polyethylene glycol (PEG). A particularly efficient method comprises two successive precipitations by using 3.5% PEG to remove any lipids, followed by 12% PEG to precipitate the IgY. A variant protocol includes an emulsification step, adding one volume of chloroform to one volume of egg yolk rather than using fractional precipitation [49,50].

IgY can also be purified by conventional ion exchange chromatography [51]. Another strategy, useful as an additional “polishing” step, relies on thiophilic adsorption chromatography (TAC) in which the target protein adsorbs to a sulphone thioether ligand in an interaction mediated predominantly by aromatic residues [52–54]. The elution conditions are very mild compared with conventional methods used to purify antibodies, such as protein A, G, or L, none of which bind to IgY. Nevertheless, purification strategies or polishing steps based on affinity ligands might be helpful, in particular when high purity is desired. Anti-IgY antibodies and synthetic ligands [55,56] are available, but this spectrum of reagents could be broadened by using soluble IgY receptor constructs or other affinity molecules as affinity medium. For instance, SSL7, the superantigen-like protein 7 from Staphylococcus aureus can be used for affinity purification of IgY (unpublished data). Additionally, recombinant expression of CHIIR in mammalian cells and in Escherichia coli is highly efficient and can potentially provide a highly homogeneous protein fraction (unpublished data).

Polyclonal preparations of IgY are suitable for many routine applications. In some diagnostic approaches, however, the use of monoclonal reagents is imperative for accuracy, reproducibility and standardisation. Even though hybridoma technology has been applied to avian species, there are technical obstacles, which together with low secretion rates of fusion lines limit its efficacy [57,58]. These obstacles can, however, be circumvented by using recombinant antibody technologies to address the need for monoclonal IgY.

An antibody essentially represents the sum of its antigen-binding moieties and the Fc portion which is essential for dimerization, effector functions and facilitates detection using conventional secondary reagents. When deciding on a reagent for a particular application, it is important to consider whether an authentic fully avian antibody is required or whether parts may in fact be derived from other species. Both avian IgY and chimeric IgY with avian constant domains and murine binding moieties have recently been produced [59,60]. In these studies, despite their heterologous origins, transfected mammalian cells were able to stably express different IgY-based constructs.

The successful secretion of immunoglobulins from mammalian cells requires that chaperones interact with nascent immunoglobulin chains and guide their folding and assembly. Binding immunoglobulin protein (BiP) binds transiently to most domains of the Ig heavy chain (CH) and some variable regions of the light and heavy chain (VH and VL) [61,62]. BiP provides a site for covalent attachment of CH and interacts stably with BiP in the absence of light chains [63]. Pronounced differences in the amino acids sequences within the antibody constant domains of antibodies from birds and mammals and the potential loss of specific interaction sites for chaperones with the nascent immunoglobulin chains might conceivably affect the efficiencies with which mammalian cells can secrete avian antibodies. For instance, IgY was found to be more efficiently secreted than IgG1, possibly as a result of less stringent control by the ER secretion machinery [60]. Since having efficient and economic ways of producing antibodies is always desirable, yields might in some cases be improved by using the binding moieties from pre-existing murine hybridomas to generate chimeric IgY. Moreover, the enormous diversity of the synthetic antibody libraries available today means that immune animals are not necessarily needed to derive suitable binders. Indeed, frameworks of synthetic human [64] and avian [65] variable regions have been successfully converted to their IgY derivatives and produced in eukaryotic hosts.

The primary sequence of the IgY heavy chain provides two potential N-linked glycosylation sites, both of which are located in the Fc region, namely Asn308 and Asn407 [17]. Carbohydrate analysis of native IgY revealed mono-glycosylated oligomannose type oligosaccharides, oligomannose type oligosaccharides and biantennary complex type oligosaccharides [66]. The first two of these have been reported as being the major glycoforms in IgY from different species [66–68] and are attributed to the C3 glycosylation site [69]. Additionally, a terminal sialic acid was identified in native IgY. No significant differences between the overall glycosylation pattern of native and recombinant IgY produced in mammalian cells could be detected using common lectins, thereby confirming that recombinant IgY from this source closely resembles the native immunoglobulin [60]. However, recombinant production of IgY in different hosts is likely to result in variable glycosylation patterns. As a result, the biochemical properties of recombinant and native IgY are likely to differ. Since glycosylation of immunoglobulins is not only implicated in a variety of physiological mechanisms but also influences their physicochemical behaviour, recombinant IgY may not always be suitable for all the potential applications envisaged for it.
To summarise, authentic polyclonal IgY is relatively easy to generate while recombinant antibody technology provides access to avian monoclonal antibodies. Moreover, pre-existing antibodies can now be converted to IgY when necessary for specific individual applications.

4. Therapeutic potential of IgY

Eggs constitute a very common component of our diet and are therefore tolerated by the human immune system. Topical administration of IgY may therefore represent an attractive approach to immunotherapy with a reduced risk of toxic side effects. While it is now widely accepted that IgY applied to human mucosal surfaces does not exhibit any immunogenicity, potentially detrimental effects might be anticipated in patients that are sensitized against egg proteins (including IgY), but this aspect is discussed later in the context of assay performance (see Section 6). Although immunogenic when applied systemically, the oral uptake of IgY antibodies opens up new possibilities for therapeutic interventions with respect to a variety of pathologies including, but not limited to, pulmonary or gastrointestinal infections (for overview see Table 1) [70]. Such approaches have been effective in reducing bacterial and viral loads in animal studies as well as in clinical trials in human cohorts [71–73].

Besides being suitable in approaches that target infective processes, IgY has been suggested for blocking, inhibition and delivery in those pathological conditions which demand specific reagents in substantial amounts. Chicken antibodies are well established as anti-toxins and/or for passive vaccination. For instance, specific anti-venom IgY can neutralize bacterial toxins [117] and be used to treat snake bites [118–125]. Indeed, anti-venom IgY can provide a higher bioactivity than antidotes raised in horses [126]. In such applications, egg yolks can provide a continuous supply of potentially superior reagents.

Today’s consumers have become increasingly interested in foods that supposedly promote health and reduce the risk of disease. Incorporating egg yolks of immunized chickens into certain food-stuffs, for example drinking yoghurt or mouthwash can provide the consumer with a functional food that can potentially protect against pathogens (so-called “edible vaccines”) without him or her having to consume synthetic pharmaceuticals [107,127–130]. A potential drawback of IgY in some therapeutic or prophylactic approaches is its reduced stability under harsh conditions such as an acidic environment. This is especially true for gastrointestinal applications. Different strategies to improve the therapeutic efficacy have therefore been evolved including a variety of techniques for stabilizing or controlling the release of IgY [86,131–133].

So far, the therapeutic interventions mentioned above are all confined to polyclonal native IgY obtained from egg yolk after immunization of hens. In contrast, the therapeutic potential of recombinant monoclonal IgY molecules remains to be explored, but it is perhaps here where the greatest potential of IgY paratopes fused to human Fc regions lies.

5. Avian antibody libraries

Applying combinatorial approaches in biology and chemistry demands high efficiency and where possible, simple and straightforward techniques. Chicken therefore provide an ideal basis for generating large immune antibody fragment libraries as compared to most mammalian species [134]. The inherent complexity of mammalian diversification mechanisms can make it difficult to recover antibody sequences. This is especially true in humans and mice. The genetic organization of these mammals is based on the modular use and recombination of a broad panel of V, D, and J segments which are further diversified by several different mechanisms. Therefore, accessing and amplifying mouse and human repertoires requires a large set of different oligonucleotides to cover the entire set of V segments which is prone to preferential amplification of high abundance transcripts and the potential loss of particular V segments during PCR. In chickens, genetic diversification is achieved differently. Both the heavy and light chain loci consist of single functional V and J genes, (and D segments for the heavy chain) that are rearranged using conventional V(D)J recombination mechanisms. In order to generate a large, diverse antibody repertoire and to allow affinity maturation upon antigen priming avian species utilize a unique mode of DNA recombination, termed gene conversion [reviewed in [135]]. In this process, short DNA segments from non-functional V pseudogenes located upstream are inserted into the rearranged gene. These modulate the primary structure and, hence the binding characteristics of the resulting immunoglobulin. However, the 5’- and 3’-ends of the rearranged gene remain unaltered thus allowing the diversity of the chicken humoral immune system to be recovered by the use of only two pairs of primers.

The first avian repertoires were cloned more than a decade ago [134,136]. Somewhat surprisingly, at first little attention was paid to those libraries, a fact that might be attributed to a lack of familiarity with chicken immunization and the need for established recombinant antibody technologies. Over the past few years, chicken libraries have attracted wider interest and accordingly, reports on the isolation of chicken-derived antibody fragments have steadily increased (for an overview see Table 2).

The targets for these antibodies have included difficult antigenic structures such as haptens, highly conserved proteins and complex crude extracts. Interestingly, the avian VH/VL scaffold has been employed not only for the generation of immune but also naive as well as semi-synthetic single chain antibody (scFv) libraries [143]. This approach allows entirely avian recombinant antibody formats aimed especially at diagnostics.

The exclusive use of single variable region genes makes the humanization of avian antibody fragments more practical than the humanization of rodent antibodies with their plethora of variable region genes. This could be shown for the engineering of an anti-prion and an anti-IL12 antibody [153,154]. Human frameworks and CDR grafting followed by further optimization were used to provide the proof of principle for this approach.

In summary, the generation and use of avian immune repertoire libraries represent a powerful approach with the potential to both complement established methods and to provide novel and original approaches. In addition, the different spectrum of epitopes recognized by the avian immune system could facilitate the development of novel therapeutics, particularly if the technology of chimeric chicken/mammalian fusions can be fully exploited.

6. Performance of IgY in immunoassays

Generally, one of the most intriguing and extraordinary characteristics of IgY is the lack of most, if not any, interactions with mammalian immune components. This makes IgY especially suited to applications in which the use of its mammalian counterparts is prone to unwanted cross-reactivities. For instance, in proteomics, pretreating of serum samples with IgY to specifically neutralize highly abundant serum components was found to improve downstream analyses [155]. In another study the identification of underrepresented serum proteins and disease marker candidate discovery was simplified when specific IgY was used as a blocking reagent [156,157]. This approach was facilitated by the general characteristics of IgY such as the ease of production and the low incidence of cross-reactivity.
In the case of immunoassays, homologous mammalian immunoglobulins may have deleterious effects on the performance of many different types of immunoassays. In particular, approaches using immunoglobulins as bioactive molecules to capture or detect the analyte are often affected by heterophilic antibodies and/or high levels of non-specific binding. In addition, antigen-independent specific binding via immunoglobulin Fc receptors or lectins and non-immunoglobulin-based interactions, e.g. those mediated by complement factors [158], can result in false-positive and false-negative results [159,160]. As recently summarized [159],
estimates of the prevalence of assay interference by heterophilic antibodies range from 1 to 80% [161–166]. A more thorough analysis of over 11,000 sera in an anti-CEA assay format revealed that about 4% of the results were potentially false [167]. Approaches to eliminate heterophilic antibody interference include the removal or modulation of Fc receptors [167,169]. It is unlikely, however, that a single method can resolve these problems [170]. Alternatively, recombinant antibody fragments [173] such as scFvs have low functional affinity for the human IgG Fc region and light chains from a chicken hybridoma cell line [59]. Additionally, Greunke et al. could demonstrate that mammalian cells could express a variety of artificial IgY constructs including chimeric IgY antibodies and homodimeric scFv-contracts with the latter showing increased secretion efficiencies [60].

Recombinant avian library-derived antibody fragments, such as scFvs have low functional affinities since they are monovalent. The obvious advantages over their mammalian homologues in certain applications such as in vivo investigations as early as 1912 [177] could be used for immunocapture in ELISA and could be readily conjugated to colloidal gold nanoparticles [66].

Although most currently used immunostests are based on murine monoclonal antibodies, we have recently provided further evidence for the potential of the use of monoclonal IgY [60,175] as a way of avoiding interference by RF and heterophilic antibodies in human serum samples [175]. Work in our laboratory has shown that monoclonal and polyclonal IgY antibodies bind neither to mammalian FcY receptors CD64 and CD16A [175] nor to the human high affinity IgE receptor, despite similarities in the amino acid sequences of human IgE and avian IgY. The low degree of relationship between mammalian and avian Fc receptors [27,31,176,177] explains these findings.

For some diagnostic applications, the advantages of IgY may be undermined by the prevalence of anti-chicken antibodies in certain individuals. Although various hen-egg proteins were implicated in allergies by both in vivo and in vitro investigations as early as 1912 [178], reports on the occurrence of human IgY-specific antibodies are scarce and are focussed on IgE-mediated hypersensitivity reactions. One study [179] demonstrated that 15 in 28 egg-allergic patients exhibited specific IgE binding against one or more egg yolk-derived antiviral chicken immunoglobulins. In contrast, according to another study the overall allergenic potential of IgY in animal models appears to be low [180]. To what extent IgY-specific antibodies of IgG, the isotype that is most relevant in immunological analyses, occur in individuals sensitized to egg yolk remains to be established.

Yet another potential source of unwanted interference in immunoassays might result from the interaction of carbohydrate binding serum proteins such as mannose-binding lectin (MBL) with N-linked glycostructures in the IgY Fc region [17,181]. However, such problems largely depend on the particular expression host needed to produce the IgY and could conceivably be counteracted

| Antigens | Size | Source | Authors |
|----------|------|--------|---------|
| Allergens (Fel d 1, nAmb a 1, YJV extract) | $7.2 \times 10^8$ | Spleen and bone marrow | Finlay et al. [137] |
| BSA, lysozyme, bovine thyroglobulin | $2.7 \times 10^7$ | Bursal lymphocytes of naive chicken | Davies et al. [134] |
| C-reactive protein (CRP) | $3 \times 10^7$ | Spleen and bone marrow | Leonard et al. [138] |
| Domoic acid-BSA | $3.1 \times 10^5$ | Spleen and bone marrow | Finlay et al. [139] |
| Fluorescein-BSA | $9.6 \times 10^9$, $5 \times 10^7$ (scFv-libraries), $3.8 \times 10^7$ (chimeric Fab-library) | Spleen and bone marrow | Andris-Widthopf et al. [140] |
| Fragments of SARS-CoV spike protein | $5 \times 10^7$ | Spleen | Lee et al. [141] |
| Holotungstic | $2.5 \times 10^7$ (original library) $1.2 \times 10^7$ (chain-shuffled library) | Spleen | Fitzgerald et al. [142] |
| Haptens, proteins, viruses | $2 \times 10^9$ | Naive bursae | Van Wyngaardt et al. [143] |
| Human clan III Ig | $>8.5 \times 10^8$ | Bone marrow and spleen | Cary et al. [40] |
| Human LDL | nd | Spleen | Sato et al. [144] |
| IBDV strain 002/73 | $1.5 \times 10^7$ and $7.5 \times 10^7$ | Spleen and bone marrow | Bowes et al. [146] |
| Live endothelial progenitor cells | $2.7 \times 10^8$ | Spleen | Chiliza et al. [147] |
| Mixture of aldolase and actate dehydrogenase | $6.7 \times 10^8$ | B cells from bone marrow and peripheral blood lymphocytes | Hof et al. [148] |
| of Plasmodium falciparum, variant surface glycoprotein of Trypanosoma sp., and purified malignant catarhal fever virus | | | |
| Mixture of autoantigens | $2 \times 10^8$ and $1 \times 10^8$ | Murine serum albumin | Yamanaka et al. [136] |
| | $1.4 \times 10^7$ | Spleen | Foo et al. [149] |
| | $1 \times 10^7$ | Non-structural protein (NSP) 3ABC from foot-and-mouth disease virus (FMDV) | Spleen | Leu et al. [150] |
| | $2.4 \times 10^5$, $3.5 \times 10^5$ | Spleen | Leu et al. [150] |
| | $1.65 \times 10^8$ | Synthetic peptide | Pitaksaikul et al. [151] |
| | $5 \times 10^7$ | TNP conjugate Insect venoms | Meyer et al. [152] |
| | $5 \times 10^8$ | | Greunke et al., Manuscript in preparation |
by deleting the particular asparagine residues responsible for the interaction. Both N-glycosylation sites can be eliminated in recombinant IgY without severely affecting binding behaviour and production efficiency (unpublished observation).

Although it may well be worthwhile to convert many of the existing hybridoma-derived antibodies used in problematic immunoassays into recombinant IgY, the biochemical characteristics of such murine/avian chimeras might differ from those of the authentic avian antibody. Interference may still arise from proteins that interact specifically with rodent immunoglobulin variable regions such as HAMA, a potential consequence of therapeutic interventions using chimeric therapeutic antibodies. Today, however, since humanized antibodies are becoming more readily available for clinical applications, a decrease in the prevalence of HAMA can be expected.

Another approach to improving the reliability of immunoassays based on IgY and one of its receptors was developed very recently.

In immunoassays aimed at detecting circulating Ig species specific for pathogens or other antigens, pools of human sera represent the immunologist’s first choice as controls. These are sometimes not readily available, are usually expensive and vary in quality. Instead, artificial substitutes for human reference sera specific for virtually any protein of interest could easily be established (unpublished results) by using avian polyclonal or (under certain circumstances) monoclonal IgY complexed with the IgY-specific CHIR-AB1 ectodomain which has been genetically fused to human Ig Fc domains, as the binding moiety.

7. Conclusions

In summary, the ready availability of polyclonal egg-yolk immunoglobulins and the rise of recombinant technologies that can generate monoclonal IgY have focussed attention on the useful characteristics of avian antibodies. Moreover, the fact that monoclonal IgY and IgY-like constructs can now be obtained from combinatorial libraries, sometimes without immunisation, is likely to make IgY in all its manifestations much more widely used in research, diagnostics and therapeutics.

References

[1] Asaoka H, Nishinaka S, Wakamiya N, Matsuda H, Murata M. Two chicken monoclonal antibodies specific for heterophil Hanganutziu-Deicher antigens. Immunol Lett 1992;32:91–6.
[2] Goueli SA, Hanten J, Davis A, Ahmed K. Polyclonal antibodies against rat liver cytosolic casein kinase II (CK-2) cross-react with CK-2 from other tissues and nuclear form (PK-N2) of the enzyme. Biochem Int 1990;21: 685–94.
[3] Matsuhashi K, Horiiuchi H, Furusawa S, Horiiuchi M, Shingawa M, Matsuda H. Chicken monoclonal antibodies against synthetic bovine prion protein peptide. J Vet Med Sci 1998;60:777–9.
[4] Carlander D, Larsson A. Avian antibodies can eliminate interference due to complement activation in ELISA. Ups J Med Sci 2001;106:189–95.
[5] Vikinge TP, Askendal A, Liedberg B, Lindahl T, Tengvall P. Immobilized chicken antibodies improve the detection of serum antigens with surface plasmon resonance (SPR). Biosens Bioelectron 1998;13:1257–62.
[6] Buerstedde JM, Reynaud CA, Humphries EH, Olson W, Ewert DL, Weill JC. Light chain gene conversion continues at high rate in an ALV-induced cell line. Embo J 1990;9:921–7.
[7] McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348: 522–4.
[8] Klemperer F. Über natürliche Immunität und ihre Verwertung für die Immunisierungstherapie. Arch exp Impt Pharmakol 1893;31:356–82.
[9] Rose ME, Orlist E, Buttress N. Immunoglobulin classes in the hen’s egg: their segregation in yolk and white. Eur J Immunol 1974;4:521–3.
[10] Kowalczyk K, Daiss J, Halpern J, Roth TF. Quantitation of maternal-fetal IgG transport in the chicken. Immunology 1985;54:755–62.
[11] Lundqvist ML, Middleton DL, Radford C, Warr GW, Magor KE. Immunoglobulins of the non-galliform birds: antibody expression and repertoire in the duck. Dev Comp Immunol 2006;30:93–100.
monoclonal antibody: exploiting evolutionary distance to create antibodies specific for a conserved VH region. J Immunol 2000;164:4730–1.

41. Ohta M, Hamako J, Yamamoto S, Hatta H, Kim M, Yamamoto T, et al. Structures of asparagine-linked oligosaccharides from hen egg-yolk antibody and in vivo effectiveness of egg yolk immunoglobulins against enteric infectious disease: a review. J Med Food 2002;5:159–69.

42. Kuroki M, Ohta M, Ikemori Y, Peralta RC, Yokoyama H, Kodama Y. Protection of neonatal calves against fatal enteric colibacillosis by administration of egg yolk powder from hens immunized with K99-piliated enterotoxigenic Escherichia coli. Am J Vet Res 1992;53:2005–8.

43. Ikemori Y, Kuroki M, Peralta RC, Yokoyama H, Kodama Y. Protection of neonatal calves against enteric infectious disease: a review. J Med Food 2002;5:159–69.

44. Attallah AM, Abbas AT, Ismail H, Abdel-Raouf M, El-Dosoky I. Establishment of hapten-specific monoclonal avian IgY by conversion of Fab fragments from chicken egg yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35:433–40.

45. Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral immunization effect of anti-human rotavirus IgY and its behavior against severe gastritis in BALB/c mouse model. J Immunoassay Immunochem 2009;30:359–74.

46. Attallah AM, Abbas AT, Ismail H, Abdel-Raouf M, El-Dosoky I. Establishment of hapten-specific monoclonal avian IgY by conversion of Fab fragments from chicken egg yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35:433–40.

47. Kenten M, Haaig A. Interaction of BIP with newly synthesized immunoglobulin light chain molecules: cycles of sequential binding and release. Embry J 1992;11:1573–81.

48. Hendershot L, Brog J, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgY: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000;10:477–86.

49. Suzuki N, Lee YC, Strotmann J. The species-specific N-glycosylation of chicken serum IgY. Glycobiology 2004;14:275–92.

50. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J Med Food 2002;5:159–69.

51. Hendershot L, Weigler J, Carlander D, Olesen H, Wejaker PE, Johannesson M, et al. Oral immunization effect of anti-human rotavirus IgY and its behavior against severe gastritis in BALB/c mouse model. J Immunoassay Immunochem 2009;30:359–74.

52. Farrelly C, Branton D, Wanke CA. Oral ingestion of egg yolk immunoglobulin administered against Shiga toxin 1 in mouse models. Can J Microbiol 2010;56:1003–7.

53. Hendershot L, Bole D, Kohler G, Kearney JF. Assembly and secretion of heavy chain-binding protein. J Cell Biol 1987;104:761–71.

54. Ohta M, Hamako J, Yamamoto S, Hatta H, Kim M, Yamamoto T, et al. Structures of asparagine-linked oligosaccharides from hen egg-yolk antibody (IgY). Occurrence of unusual glucosylated oligosaccharide type oligosaccharide in a mature glycoprotein. Glycocon. J 1991;8:400–13.

55. Matsuda H, Mitsuda H, Nakamura N, Furusawa S, Mohri S, Kitamoto T. A chicken monoclonal antibody with specificity for the N-terminal of human prion protein. FEMS Immunol Med Microbiol 1999;23:189–94.

56. Ikemori Y, Kuroki M, Peralta RC, Diaz R, Sendo S, Ikiemori Y, Kodama Y. Passive protective effect of chicken egg yolk immunoglobulins against enterotoxigenic Escherichia coli infection in neonatal piglets. Infect Immun 1992;60:2593–7.

57. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J Med Food 2002;5:159–69.

58. Attallah AM, Abbas AT, Ismail H, Abdel-Raouf M, El-Dosoky I. Establishment of hapten-specific monoclonal avian IgY by conversion of Fab fragments from chicken egg yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35:433–40.

59. Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral immunization effect of specific antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35:433–40.

60. Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral immunization effect of specific antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35:433–40.

61. Song Q, Hou XJ, Cai KL, Li L, Liu YN, Tu W, et al. Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models. Can J Microbiol 2010;56:1003–7.

62. Hendershot L, Bole D, Kohler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol 1987;104:761–71.

63. Hendershot L, Bole D, Kohler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol 1987;104:761–71.

64. Decker S, Braren I, Gruenke K, Meyer N, Ruhl D, Brederhorst R, et al. Establishment of hapten-specific monoclonal avian IgY by conversion of antibody fragments obtained from combinatorial libraries. Biotechnol Biochem 2006;70:446–56.

65. Wenmer S, Mashau C, Fehrs J, van Wyngaardt W, du Plessis DH. Chicken scFv’s and bivalent scFv-CH(F) fusions directed against HISP65 of Mycobacte- rin bovis. Biotechnol Biochem 2010;38:407–14.

66. Matsuba M, Hamamoto M, Murakami K, Matsuji Y, Ohtsuka Y, Tochikubo T, et al. Oral immunization effect of anti-human rotavirus IgY and its behavior against severe gastritis in BALB/c mouse model. J Immunassay Immunochem 2009;30:359–77.
[94] Liou JF, Chang CW, Taiulli JJ, Yu CK, Lei HY, Chen LR, et al. Passive protection effect of chicken egg yolk immunoglobulins on enterovirus 71 infected mice. J Microbiol Immunol Infect 2010;43:95–6.

[95] Ett eradossi N, Toquin D, Abbassi H, Rivalian G, Cotte JP, Guittet M. Passive protection of specific pathogen free chicks against infectious bursal disease by in ovo injection of semi-purified egg-yolk antiviral immunoglobulins. Zentralbl Veterinarmed B 1997;44:371–83.

[96] Worrelde KL, Godiska R, Barrett TA, Kink JA. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci 2000;45:2298–305.

[97] Nguyen NH, Tumpey TM, Park JH, Byun HY, Than LD, Nguyen VD, et al. Propylphatic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS One 2010;5:e10152.

[98] Tsukamoto M, Hiroi S, Adachi K, Kato H, Inai M, Konsishi I, et al. Antibodies against avian influenza virus neutralize the pandemic influenza virus A/ H1N1. Mol Med Rep 2010;4:209–14.

[99] Sui J, Cao L, Lin H. Antibacterial activity of egg yolk antibody (IgY) against Listeria monocytogenes and preliminary evaluation of its potential for food preservation. J Food Agric Sci 2011;1:946–50.

[100] Yang J, Jin Z, Yu Q, Yang T, Wang H, Liu L. The selective recognition of antibody IgY for digestive system tumors. Chin J Biotechnol 1999;13:85–90.

[101] Sugita-Konishi Y, Ogawa M, Arai S, Kumagai S, Igimi S, Shimizu M. Blockade of tumor necrosis factor antibodies effectively treats experimental colitis in mice. Zentralbl Veterinarmed B 1997;44:371–83.

[102] Carlander D, Kollberg H, Larsson A. Retention of specificity of chicken egg yolk antibodies. BioDrugs 2002;16:433–7.

[103] LeClaire RD, Hunt RE, Bavari S. Protection against bacterial superantigen induced endotoxin shock. Clin Exp Immunol 2004;137:209–14.

[104] Kweon CH, Kwon BJ, Woo SR, Kim JM, Woo GH, Son DH, et al. Immuno-competence of chicken egg yolk antibodies against Eimeria maxima infections. Vet Parasitol 2009;163:123–6.

[105] Torche AM, Le Dimna M, Le Corre P, Mesplede A, Le Gal S, Cariolet R, et al. Immune responses after local administration of IgY loaded-PLGA microspheres in gut-associated lymphoid tissue in pigs. Vet Immunol Immunopathol 2006;109:209–17.

[106] Li XY, Jin J, McCullister TA, Stanford K, Xu Y, Liu YN, et al. Chitosan–alginate microparticles for oral delivery of egg yolk immunoglobulin (IgY). J Agric Food Chem 2007;55:2911–7.

[107] Kovacs-Nolan J, Mine Y. Microencapsulation for the gastric passage and controlled intestinal release of immunoglobulin Y. J Immunol Methods 2005;299:199–209.

[108] Davies EL, Smith JS, Birkett CR, Manser JM, Anderson-Dear DV, Young JR. Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes. J Immunol Methods 1995;186:125–35.

[109] McCormack WT, Thompson CB. Special features of the development of the chicken humoral immune system. Rev Immunol 1993;144:467–75. discussion 475–8.

[110] Yamanaka HI, Inoue T, Ikeda-Taraoka O. Chicken monoclonal antibody iso- lated by a phage display system. J Immunol 1996;157:1156–62.

[111] Finlay WJ, deVore NC, Dobrovolskaia EN, Gam A, Gooyear CS, Slater JE. Exploiting the avian immunoglobulin system to simplify the generation of recombinant antibodies to allogeneic proteins. Clin Exp Allergy 2005;35:1046–9.

[112] Leonard P, Safsten P, Hearty S, McDonnell B, Finlay WJ. Generation of high-affinity chicken egg yolk antibodies against Eimeria maxima infections. Vet Parasitol 2009;163:123–6.

[113] Peralta RC, Yokoyama H, Ikemori Y, Kuroki M, Kodama Y. Passive immunity against experimental salmonellosis in mice by orally administered hen egg-yolk antibodies specific for 14-kDa fimbrine of Salmonella enteritidis. J Med Microbiol 1994;41:29–35.

[114] Yokoyama H, Peralta RC, Umeda K, Hashi T, Icatto Jr FC, Kuroki M, et al. Prevention of fatal salmonellosis in neonatal calves, using orally administered chicken egg yolk Salmonella-specific antibodies. Am J Vet Res 1998:59:20–2.

[115] Sugita-Konishi Y, Ogawa M, Arai S, Kumagai S, Igimi S, Shimizu M. Blockade of Salmonella enteritidis passage across the basolateral barriers of human intestinal epithelial cells by specific antibody. Microbiol Immunol 2000;44:271–5.

[116] Lee EN, Sunwoo HH, Menninen K, Sim JS. In vitro studies of chicken egg yolk antibody (IgY) against Salmonella enteritidis and Salmonella typhimurium. Poult Sci 2002;81:632–41.

[117] Liu Y, Liu J, Lin L, Xu Z, Chen Y, Xue H, et al. Passive immunization of crayfish (Procambarus clarkii) with chicken egg yolk immunoglobulin (IgY) against white spot syndrome virus (WSSV). Appl Biochem Biotechnol 2009;159:750–6.

[118] Fryer J, Firca J, Leventhal J, Blondin B, Malcolm A, Ivancic D, et al. IgY anti-porcine endothelial cell antibodies effectively block human porcine xenotransplantation. Xenotransplantation 1999;6:98–109.

[119] Leventhal JR, Sato Y, Fujihara DB, Abeisski MI, Stuart PP, Anderson B, et al. Altered infection of porcine endogenous retrovirus by “protective” avian antibodies: implications for pig-to-human xenotransplantation. Transplant Process 2001;33:690.

[120] Lee SB, Mine Y, Stevenson RM. Effects of hen egg yolk immunoglobulin in passive protection of rainbow trout against Yersinia ruckeri. J Agric Food Chem 2000;48:110–5.

[121] Pauly D, Dorner M, Zhang X, Hino J, Dorner M, Schade R. Monitoring of lung capacity, immunocompetence, immunoglobulin Y and antibody titers development in chickens immunized with ricin and botulinum toxins over a two-year period. Poult Sci 2009;88:281–90.

[122] Almeida CM, Kanashiro MM, Rangel Filho FB, Mata MF, Kipnis TL, da Silva WD. Development of snake antivenom antibodies in chickens and their purification from yolk. Vet Rec 1998;143:579–84.

[123] Araujo AS, Lobato ZJ, Chavez-Olortegui C, Velarde DT. Brazilian IgY-Bothrops antivenom: studies on the development of a process in chicken egg yolk. Toxicon 2005;53:739–44.
[147] Chiliza TE, Van Wyngaardt W, Du Plessis DH. Single-chain antibody fragments from a display library derived from chickens immunized with a mixture of parasite and viral antigens. Hybridoma (Larchmt) 2008;27:413–21.

[148] Hof D, Hoek MO, Raats JM. Multiple-antigen immunization of chickens facilitates the generation of recombinant antibodies to autoantigens. Clin Exp Immunol 2008;151:367–77.

[149] Food Aj, Muller JD, Yu M, Wang LF, Heine HG. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC. J Immunol Methods 2007;321:142–51.

[150] Leu SJ, Lee VC, Shih NY, Huang JJ, Liu KJ, Lu HF, et al. Generation and characterization of anti-alpha-enolase single-chain antibodies in chicken. Vet Immunol Immunopathol 2010;137:251–60.

[151] Pitaksajjakul P, Lekcharoensuk P, Upragarin N, Barbas 3rd CF, Ibrahim MS, Ikuta K, et al. Protein depletion using IgY from chickens immunised with human protein 3ABC. J Immunol Methods 2007;321:142

[152] Meyer M, Belke DD, Trost SU, Swanson E, Dieterle T, Scott B, et al. A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. Faseb J 2004;18:1312–4.

[153] Tsursshita N, Park M, Pakabunto K, Ong K, Avdalovic A, Fu H, et al. Humanization of a chicken anti-IL-12 monoclonal antibody. J Immunol Methods 2004;295:9–19.

[154] Nishibori N, Horiuchi H, Furusawa S, Matsuda H. Humanization of chicken monoclonal antibody using phage-display system. Mol Immunol 2006;43:634–42.

[155] Huang L, Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, et al. Immunooaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005;5:3314–28.

[156] Krajc A, Stehmann C, Autelitano DJ, Vrkic AK, Hosking CG, Rice GE, et al. Protein depletion using IgY from chickens immunized with human protein cocktails. Prep Biochem Biotechnol 2009;39:221–47.

[157] Sim RB, Tsitsogiou SA. Proteases of the complement system. Biochem Soc Trans 2004;32:21–7.

[158] Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999;45:942–56.

[159] Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002;325:1–15.

[160] Lipp RW, Passath A, Leb G. The incidence of non-iatrogenic human anti-mouse antibodies and their possible clinical relevance. Eur J Nucl Med 1991;18:996–7.

[161] Thompson RJ, Jackson AP, Langlois N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects—incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. Clin Chem 1986;32:476–81.

[162] Hedenborg G, Pettersson T, Carlstrom A. Heterophilic antibodies causing falsely raised thyroid-stimulating-hormone result. Lancet 1979;2:755.

[163] Larsson A, Mellstedt H. Chicken antibodies: a tool to avoid interference by human anti-mouse antibodies in ELISA after in vivo treatment with murine monoclonal antibodies. Hybridoma 1992;11:33–9.

[164] Falchuk KR, Isselbacher KJ. Circulating antibodies to bovine albumin in ulcerative colitis and Cronh's disease. Characterization of the antibody response. Gastroenterology 1976;70:5–8.

[165] Hunter WM, Budd PS. Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: a hazard for immunoassays. Lancet 1980;2:1136.

[166] Bjerner J, Nustad K, Norum LF, Olsen KH, Borper OM. Immunoassay interference: incidence and prevention. Clin Chem 2002;48:613–21.

[167] Primus FJ, Kelley EA, Hansen HJ, Goldberg DM, "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34:261–4.

[168] Vaidya HC, Beatty RC. Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatine kinase MB by using F(ab')2 conjugate and polyclonal mouse IgG. Clin Chem 1992;38:1737–42.

[169] Ellis MJ, Livesey JH. Techniques for identifying heterophile antibody interference are assay specific: study of seven analytes on two automated immunoassay analyzers. Clin Chem 2005;51:639–41.

[170] Kuroki M, Matsumoto Y, Arakawa F, Haruno M, Murakami K, Kuwahara M, et al. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J Immunol Methods 1995;180:81–91.

[171] Warren DJ, Bjerner J, Paus E, Borper OM, Nustad K. Use of an in vivo bio- tinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 2005;51:830–8.

[172] Andersson M, Ronnmark J, Arestrom I, Nygren PA, Ahlborg N. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. J Immunol Methods 2003;283:225–34.

[173] van de Winkel JC, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993;14:215–21.

[174] Gruenke K, Braren I, Alpers I, Blank S, Sodenkamp J, Bredhorst R, et al. Recombinant IgY for improvement of immunoglobulin-based analytical applications. Clin Biochem 2008;41:1237–44.

[175] Arnon TI, Kaiser JT, West Jr AP, Olson R, Diskin R, Vierthoeck BC, et al. The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor. J Mol Biol 2008;381:1012–24.

[176] West Jr AP, Herr AB, Bjerner J, Paus E, Bormer OP, Nustad K. Use of an in vivo bio- tinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. J Immunol Methods 2003;283:225–34.

[177] Andersson M, Ronnmark J, Arestrom I, Nygren PA, Ahlborg N. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. J Immunol Methods 2003;283:225–34.

[178] van de Winkel JC, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993;14:215–21.

[179] Greunke K, Braren I, Alpers I, Blank S, Sodenkamp J, Bredhorst R, et al. Recombinant IgY for improvement of immunoglobulin-based analytical applications. Clin Biochem 2008;41:1237–44.

[180] Arron TI, Kaiser JT, West Jr AP, Olson R, Diskin R, Vierthoeck BC, et al. The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor. J Mol Biol 2008;381:1012–24.

[181] West Jr AP, Herr AB, Bjerner J, Paus E, Bormer OP, Nustad K. Use of an in vivo bio- tinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. J Immunol Methods 2003;283:225–34.

[182] Worsley DJ, Bjerner J, Paus E, Borper OM, Nustad K. Use of an in vivo bio- tinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 2005;51:830–8.

[183] Andersson M, Ronnmark J, Arestrom I, Nygren PA, Ahlborg N. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. J Immunol Methods 2003;283:225–34.

[184] van de Winkel JC, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993;14:215–21.

[185] Greunke K, Braren I, Alpers I, Blank S, Sodenkamp J, Bredhorst R, et al. Recombinant IgY for improvement of immunoglobulin-based analytical applications. Clin Biochem 2008;41:1237–44.

[186] Arnon TI, Kaiser JT, West Jr AP, Olson R, Diskin R, Vierthoeck BC, et al. The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor. J Mol Biol 2008;381:1012–24.

[187] West Jr AP, Herr AB, Bjerner J, Paus E, Bormer OP, Nustad K. Use of an in vivo bio- tinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. J Immunol Methods 2003;283:225–34.